Mode
Text Size
Log in / Sign up
N/A N=300 Randomized Single-blind Treatment

Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments

Opioid Dependence

Enrolled (actual)
300
Serious AEs
8.3%
Results posted
Mar 2020
Primary outcome: Primary: Initiation of Treatment for Opioid Dependence — 85; 74; 63; 75 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Strengths-based Case Management (SBCM) (Behavioral); Screening, Assessment, and Referral (SAR) (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
NYU Langone Health
Primary completion
Apr 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Initiation of Treatment for Opioid Dependence
85; 74; 63; 75
PRIMARY
Engagement in Treatment for Opioid Dependence
21.77; 17.72 0.29
SECONDARY
Number of Participants With Successful Outcome for Opioid Use
41; 28; 107; 121
SECONDARY
Score on World Health Organization Quality of Life (WHOQoL) Brief Questionnaire
11.23; 11.22 0.91
SECONDARY
Initiation in Participants With Higher Levels of Environmental Instability at Baseline
62.5; 57.8 0.09
SECONDARY
Engagement in Participants With Higher Levels of Environmental Instability at Baseline
22.16; 19.89 0.54

Summary

This study will compare the effects of brief strengths-based case management (SBCM) to the effects of screening, assessment and referral alone (SAR) in opioid-dependent patients. Participants meeting DSM-IV criteria for opioid dependence will be randomly assigned (150 per group) to receive 1) up to 6 sessions of SBCM; or 2) SAR. Follow-up assessments will be completed at 3 and 6 months, by staff who are blinded to treatment condition.

Eligibility Criteria

Inclusion Criteria

  • Registration as patient in the ED during study screening hours;
  • Endorsement of three or more opioid dependence criteria on the DSM-IV checklist
  • Age 18 years or older;
  • Adequate English proficiency;
  • Ability to provide informed consent;
  • Self-report use of opioids in the last 30 days

Exclusion Criteria

  • Inability to participate due to emergency treatment;
  • Significant impairment of cognition or judgment rendering the person incapable of informed consent. (e.g., traumatic brain injury, delirium, intoxication);
  • Status as a prisoner or in police custody at the time of treatment;
  • Current engagement in substance use disorder treatment;
  • Residence more than 50 miles from the location of follow-up visits;
  • Inability to provide sufficient contact information (must provide at least 2 reliable locators);
  • Unavailable for follow-up (e.g., planning to relocate within 6 months)
  • Prior participation in the current study.
  • Current participation in a research study related to substance use.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02586896). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search